Journal article
Quinone oxidoreductase-2-mediated prodrug cancer therapy.
- Abstract:
-
DNA-damaging agents are widely used in cancer treatment despite their lack of tumor specificity. Human NQO2 (quinone oxidoreductase-2) is an atypical oxidoreductase because no endogenous electron donor has been identified to date. The enzyme converts CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide], in the presence of the synthetic nicotinamide cofactor analog EP0152R, to a cytotoxic bifunctional alkylating agent. NQO2 activity in hepatocellular tumor tissue is higher than that in other cancer...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Science translational medicine
- Volume:
- 2
- Issue:
- 40
- Pages:
- 40ra50
- Publication date:
- 2010-07-01
- DOI:
- EISSN:
-
1946-6242
- ISSN:
-
1946-6234
- Source identifiers:
-
108380
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:108380
- UUID:
-
uuid:360a29ed-28c0-4d52-be87-877eb01745e7
- Local pid:
- pubs:108380
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2010
If you are the owner of this record, you can report an update to it here: Report update to this record